Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer

Core Viewpoint - SpectronRx and Cellectar Biosciences have entered into a commercial supply agreement for the manufacture of iopofosine I 131, a novel cancer therapy aimed at treating advanced cancers, particularly Waldenstrom's macroglobulinemia [1][2][3] Company Overview - SpectronRx specializes in radiopharmaceutical contract development and manufacturing, with capabilities in isotope production and clinical trial support [5][6] - Cellectar Biosciences focuses on the discovery and commercialization of cancer treatments, leveraging its proprietary Phospholipid Drug Conjugate delivery platform [7][8] Partnership Details - The partnership aims to enhance Cellectar's supply network and manufacturing capabilities for iopofosine I 131, which has shown promising efficacy in clinical studies [2][3] - SpectronRx will utilize its facilities in Indiana and Belgium for the production of iopofosine I 131, facilitating global market distribution [2][3] Product Development - Iopofosine I 131 has demonstrated impressive results in the CLOVER-WaM pivotal study for patients with relapsed or refractory Waldenstrom's macroglobulinemia, with a New Drug Application submission planned soon [2][3] - The drug is also being evaluated in Phase 2 studies for relapsed or refractory multiple myeloma and central nervous system lymphoma, as well as in a Phase 1b study targeting pediatric patients with high-grade gliomas [2][3] Regulatory Status - Iopofosine I 131 is currently investigational and has received Orphan Drug and Fast Track Designations from the FDA for various cancer indications [3]